Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
Trackers› Clinical trials› New York
Clinical trial register · United States · industry-sponsored

Clinical Trials in New York, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
Texas 53 California 44 Florida 32 Michigan 31 New York 29
Narrow the registerReset
Recruitment status
Phase
Target enrolment
to

Trials with a site in New York

29 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
A Study of IOV-5001 in Adults With Advanced Solid Tumors
NCT07743723Advanced Solid Tumors, Non-Small Cell Lung Cancer, Triple Negative Breast Cancer (TNBC), Colorectal Cancer
Iovance Biotherapeutics, Inc.
Phase 1/2
106
New York
2026-09
Recruiting
LigaChem Biosciences, Inc.
Phase 1/2
191
Massachusetts, New York, South Carolina, Texas
2026-08
Recruiting
VelaVigo Bio Inc
Phase 1/2
230
California, Michigan, New York, Texas, Virginia
2026-07-30
Recruiting
Gilead Sciences
Phase 1
174
Massachusetts, Michigan, New Jersey, New York, Texas
2026-06-02
Recruiting
Genmab
Phase 1
121
Connecticut, Michigan, New York
2026-04-07
Recruiting
Eikon Therapeutics
Phase 1/2
160
California, Florida, New Jersey, New York, Texas
2026-01-20
Recruiting
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
NCT07197554Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC), Biliary Tract Cancer (BTC)
SEED Therapeutics, Inc.
Phase 1
171
California, Massachusetts, New York, Texas
2025-12-01
Recruiting
Pyxis Oncology, Inc
Phase 1/2
220
California, Florida, Illinois, Massachusetts, New York, Oklahoma, Pennsylvania, Texas
2025-04-15
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Recruiting
Accent Therapeutics
Phase 1/2
218
Colorado, Florida, Michigan, Missouri, Nebraska, New York, Tennessee, Texas
2025-03-21
Recruiting
A Phase I Study of SIM0505 in Participants With Advanced Solid Tumors
NCT06792552Advanced Solid Tumors, Platinum Resistant Ovarian Cancer, Fallopian Tube Cancer, Renal Cell Carcinoma (RCC)
NextCure, Inc.
Phase 1
738
Florida, Georgia, Louisiana, Massachusetts, New Jersey, New York, Tennessee, Texas
2025-02-26
Recruiting
Bristol-Myers Squibb
Phase 1/2
413
California, Colorado, New Jersey, New York, North Carolina, Washington
2025-02-17
Recruiting
A Study of MGC028 in Participants With Advanced Solid Tumors
NCT06723236Advanced Solid Tumors, NSCLC Adenocarcinoma, Cholangiocarcinoma, Pancreatic Carcinoma
MacroGenics
Phase 1
124
California, Massachusetts, Michigan, New York, Texas, Utah
2025-02-13
Recruiting
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
NCT06657222Advanced Solid Tumors, HNSCC, SCLC, NSCLC
Gilead Sciences
Phase 1/2
250
Connecticut, Florida, Massachusetts, Minnesota, Missouri, New York, Ohio, Texas
2024-12-13
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
240
California, Connecticut, Illinois, Michigan, New York, North Carolina, Pennsylvania, Texas
2024-09-23
Active, closed
First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT06239467Advanced Cancer, Breast Cancer, Advanced Solid Tumors, PI3K Gene Mutation
OnKure, Inc.
Phase 1
200
California, Colorado, Massachusetts, Nevada, New York, Tennessee, Virginia, Washington
2024-02-26
Recruiting
Gilead Sciences
Phase 1
278
Massachusetts, New York, Texas
2024-01-09
Recruiting
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
NCT06040541Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Revolution Medicines, Inc.
Phase 1
604
California, Connecticut, Florida, Maryland, Massachusetts, New York, North Carolina, Ohio
2023-09-07
Recruiting
AskGene Pharma, Inc.
Phase 1/2
594
New York, Pennsylvania
2023-08-02
Recruiting
Incyte Corporation
Phase 1
570
California, Massachusetts, Michigan, New Jersey, New York, Pennsylvania, Rhode Island, Texas
2023-07-24
Active, closed
Bristol-Myers Squibb
Phase 1/2
100
California, Connecticut, New Jersey, New York
2023-06-06
Recruiting
Astellas Pharma Global Development, Inc.
Phase 1
798
Connecticut, Florida, Iowa, Kentucky, Michigan, Minnesota, New York, Ohio
2023-03-13
Recruiting
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
NCT05379985Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumors
Revolution Medicines, Inc.
Phase 1/2
754
California, Florida, Georgia, Louisiana, Maryland, Massachusetts, New York, Ohio
2022-05-31
Recruiting
Merck Sharp & Dohme LLC
Phase 1
830
Florida, Michigan, New Jersey, New York, Virginia, Wisconsin
2021-12-17
Active, closed
AbbVie
Phase 1
520
California, Colorado, Connecticut, Illinois, Indiana, Louisiana, Michigan, New York
2021-10-13
Active, closed
Regeneron Pharmaceuticals
Phase 1/2
548
California, Colorado, Florida, Illinois, Iowa, Michigan, New Jersey, New York
2020-12-21
Active, closed
Genentech, Inc.
Phase 1
498
California, Connecticut, Florida, Massachusetts, New York, Oklahoma, Pennsylvania
2020-07-29
Active, closed
Fujifilm Pharmaceuticals U.S.A., Inc.
Phase 1
96
Arizona, Colorado, Massachusetts, New York, Ohio, Texas, Wisconsin
2019-11-14
Active, closed
Novartis Pharmaceuticals
Phase 1
120
New York, Oregon, Texas
2019-10-30
Rows per page Showing 1–29 of 29
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 17 October 2026. https://priyalifescience.com/clinical-trials-usa/state/new-york

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 29 of those studies with a site in New York that also match the filters currently applied.

How many clinical trials are recruiting in New York?

21 of the 29 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 1 have not yet opened recruitment, 7 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (New York), 29 studies
PhaseStudiesRecruitingShare
Phase 1161155.2%
Phase 1/2131044.8%

Most active sponsors

Lead sponsors with the most studies (New York)
Lead sponsorStudiesRecruiting
Gilead Sciences33
Bristol-Myers Squibb21
Regeneron Pharmaceuticals21
Revolution Medicines, Inc.22
AbbVie10
Accent Therapeutics11
AskGene Pharma, Inc.11
Astellas Pharma Global Development, Inc.11
Eikon Therapeutics11
Fujifilm Pharmaceuticals U.S.A., Inc.10
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.